The COVID-19 pandemic has underlined the need for less well-resourced countries to improve access to medicines, vaccines, medical devices and other health products by building their own production capacities.
As part of efforts to build up domestic manufacturing of medicines and vaccines in lower-income countries, the World Health Organization is setting up a new advisory group on local production and technology transfer and is looking for experts to sit on it.
“Strategic local production of medicines, vaccines and other health technologies in low- and middle-income countries has assumed huge significance” in the context of the ongoing COVID-19 pandemic, the WHO said, noting, with not a little
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.
The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.
